Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 363 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: LDL Clear all

Conditions: Hypercholesterolemia
Interventions: BiosLife Complete, Placebo; Dietary Supplement
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hypercholesterolemia
Interventions: LGT209, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Miami Gardens, Florida • Fargo, North Dakota

Conditions: Familial Hypercholesterolemia
Interventions: LDL Apheresis; Procedure
Lead sponsor: Emory University; Other
Eligibility: 3 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Dyslipidemias, Cardiovascular Diseases, HIV Infections
Interventions: Alirocumab, Placebo; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypercholesterolemia
Interventions: packaging; Behavioral
Lead sponsor: Durham VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Durham, North Carolina • Raleigh, North Carolina

Conditions: Dyslipidaemias
Interventions: GW590735, fenofibrate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 45
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more

Conditions: Hypercholesterolemia
Interventions: AZD8233; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy, Healthy Volunteer, Healthy Volunteers, Healthy Adult, Healthy Male and Female Subjects, Healthy Subjects, Healthy Volunteers Only, Healthy Non-smokers
Interventions: Negative control, Avocado, Fat and fiber addition; Other
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Obesity
Interventions: Low carbohydrate diet, Moderate carbohydrate diet, High carbohydrate diet; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 4
States / cities: Boston, Massachusetts • Framingham, Massachusetts

Conditions: Hypercholesterolemia
Interventions: bempedoic acid 180mg, placebo, evolocumab; Drug · Other
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 43
States / cities: Little Rock, Arkansas • Los Angeles, California • Greenwich, Connecticut + 32 more

Conditions: Hypercholesterolemia
Interventions: Atorvastatin, Ezetimibe, Alirocumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 41
States / cities: Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more

Conditions: Hypertriglyceridemia
Interventions: Fish oil (90% triglycerides), Fish oil (60% triglycerides), Fish oil (ethyl esters), Soy oil; Dietary Supplement
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: HIV Infections, Cardiovascular Disease
Interventions: rosuvastatin; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Diabetes Mellitus, Macular Edema
Interventions: Vitamin E; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Alirocumab 150 mg, Inclisiran; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 996 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diabetic Nephropathy
Interventions: Lisinopril, Nifedipine, Simvastatin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 1999
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 30 Years to 50 Years
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: New York, New York

Conditions: Human Immunodeficiency Virus (HIV) Infection, Hypercholesterolemia
Interventions: Soy Pretzel, Wheat Pretzel; Dietary Supplement · Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Heart Transplant
Interventions: Evolocumab; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 80 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Heart Diseases
Interventions: Exercise training; Other
Lead sponsor: East Tennessee State University; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 1998
U.S. locations: 1
States / cities: Johnson City, Tennessee

Conditions: Work-related Injury
Interventions: individual -Brief Motivational Intervention (BMI), Group (Group Problem Solving), Standard of Care (OSHA 10 Safety Cards); Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hyperlipidemia
Interventions: ARI-3037MO; Drug
Lead sponsor: Arisaph Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 19
States / cities: Chino, California • Fort Lauderdale, Florida • Jacksonvile, Florida + 12 more

Conditions: Hypercholesteremia
Interventions: phytosterol; Drug
Lead sponsor: The Cooper Institute; Other
Eligibility: 20 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

The Effect of BiosLife on Serum Lipids

Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia

Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers

Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)

Cholesterol Medication Packaging Study

Dyslipidemia Study Investigating The Increase In "Good Cholesterol"

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.

Avocado and Postprandial Responses

Metabolic Fuels Study

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

Effect of Fish Oil on Plasma Triglycerides in Adults

Effect of Rosuvastatin on Endothelial Function

Laser and Medical Treatment of Diabetic Macular Edema

Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice

Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes

The Prevent Coronary Artery Disease Trial

Soy Modulation of Immune Activation, LDL- Levels, and Lowering Inflammation by Pretzel Isoflavone Dietary Intervention

Impact of Evolocumab in Cardiac Transplant Patients With CAV

Exercise as a Modulator of Immune Risk Factors for Ischemic Heart Disease

VALES+Tú: Targeting Psychosocial Stressors to Reduce Latino Day Laborers (LDL) Injury Disparities

Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia

Phytosterol Supplementation and Cardiovascular Risk